Clinical trial for Non-small Cell Lung Cancer
Official title Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
ClinicalTrials.gov ID: NCT05061550
What this study is testing
What is Durvalumab?
An investigational intravenous drug being studied as a potential treatment for early-stage non‑small cell lung cancer. It is designed to block the PD‑L1 protein on cancer cells, helping the immune system recognize and attack the tumor.
Also referred to as IMFINZI.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will look at how safe and effective several new drug combinations are when given around the time of surgery for early‑stage lung cancer.
- Who it's for
- It is for adults who have resectable, early‑stage non‑small cell lung cancer and are scheduled for surgery.
- What's involved
- Participants will receive one of several drug combinations with standard chemotherapy, then have surgery, and may receive additional treatment after surgery. They will have regular clinic visits and medical tests to monitor safety and response.
- Time commitment
- The study lasts about 12–18 months, with multiple clinic visits before and after surgery and follow‑up appointments to track progress.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 95
You may be able to join if
- Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).
- WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and bone marrow function.
- Provision of tumour samples (newly acquired or archival tumour tissue [≤ 6 months old]) to confirm Programmed death-ligand 1 (PD-L1) status...
- Adequate pulmonary function.
You likely can't join if
- Participants with sensitising EGFR mutations or ALK translocations.
- Participants with baseline PD-L1 expression status \<1% (Arms 6 and 7 only).
- Active or prior documented autoimmune or inflammatory disorders.
- Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases...
- History of another primary malignancy.
- Participants with small-cell lung cancer or mixed small-cell lung cancer.
See the full eligibility criteria
- Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).
- WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and bone marrow function.
- Provision of tumour samples (newly acquired or archival tumour tissue [≤ 6 months old]) to confirm Programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK)...
- Adequate pulmonary function.
- Participants with sensitising EGFR mutations or ALK translocations.
- Participants with baseline PD-L1 expression status \<1% (Arms 6 and 7 only).
- Active or prior documented autoimmune or inflammatory disorders.
- Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases, serious chronic gastrointestinal conditions associated with diarrhoea...
- History of another primary malignancy.
- Participants with small-cell lung cancer or mixed small-cell lung cancer.
- History of active primary immunodeficiency.
- History of non-infectious interstitial lung disease (ILD) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Participants who have preoperative radiotherapy treatment as part of their care plan.
- Participants who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon at baseline, to obtain potentially curative resection of primary tumour.
- QTcF (QT interval corrected by Fridericia's formula) interval ≥ 470 ms.
- Any medical contraindication to treatment with chemotherapy as listed in the local labelling.
- Participants with moderate or severe cardiovascular disease.
- Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions.
- Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains), anti-PD-1, anti-PD-L1, and anti-PD-L2...
- Current or prior use of immunosuppressive medication within 14 days before the first dose of study interventions.
- Active or uncontrolled infections including HBA, HBV, HCV, and HIV.
The study team makes the final eligibility decision.
Where it is enrolling
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- New Haven, Connecticut, United States
- Chicago, Illinois, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Omaha, Nebraska, United States
- Cleveland, Ohio, United States
- Pittsburgh, Pennsylvania, United States
- Chattanooga, Tennessee, United States
- Memphis, Tennessee, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Fairfax, Virginia, United States
- Edmonds, Washington, United States
- Seattle, Washington, United States
- Ghent, Belgium
- Roeselare, Belgium
- Winnipeg, Manitoba, Canada
- Montreal, Quebec, Canada
+ 46 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 95 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Little Rock, Arkansas, United States; Los Angeles, California, United States; New Haven, Connecticut, United States; Chicago, Illinois, United States; Baltimore, Maryland, United States; Boston, Massachusetts, United States and 60 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.